Newsletters

[Fierce Pharma] Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive Phase III trial in metastatic hormone-sensitive prostate cancer. The Phase III Talapro-3 trial met its primary endpoint by showing the combo of Talzenna and Pfizer and Astellas’ prostate cancer drug Xtandi reduced the risk of tumor progression or death compared with Xtandi and placebo.

[Cell Death & Disease] Researchers identified a STAT1/lactate/NFκB1/MCP-1 positive feedback mechanism as a driver of prostate cancer progression and resistance to radiotherapy that functioned by interaction to macrophages, which could be potential therapeutic targets for the advanced prostate cancer.

[Molecular Therapy Oncology] Researchers discovered that the loss of phosphatase and tensin homolog (PTEN) function, in combination with elevated poly(ADP-ribose) polymerase expression, significantly shortens the survival of prostate cancer patients.

[GI Innovation (Biospace)] GI Innovation announced that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with mCRPC in a Phase Ib clinical trial.

[Science] Investigators engineered a new class of supercharged T cells that are stronger, longer-lasting, and more precise at killing prostate cancer cells by fine-tuning how they physically interact with tumor cells.

[Université de Montréal] Université de Montréal epidemiologist Vikki Ho has been awarded a $2-million grant over five years to study how environmental and other factors contribute to the onset of colorectal cancer.

[Molecular Cancer] Researchers found that adenosine deaminase tRNA specific 2 (ADAT2)-driven tRNA A-to-I modification promotes colorectal cancer tumorigenesis and chemoresistance via HDAC7-WNT/β-catenin axis.

[Nature Communications] Scientists showed that a conserved axonal guidance cue directs enteroblasts, the immediate intestinal stem cell daughters, to selectively replace worn-out adjacent and remote enterocytes with identical frequency.

[Cancer Research] Investigators identified that the PI3K/mTOR and MAPK/ERK signaling pathways, among other pathways, are linked to the formation of myofibroblast-like cancer-associated fibroblast (CAF) and inflammatory CAF subtypes, respectively.

[NPJ Precision Oncology] Researchers integrated single-cell RNA sequencing, 119,931 cells from 25 gastric tumors, with spatial transcriptomics and bulk cohorts to delineate palmitoylation-linked states across malignant, immune, and stromal compartments.

[NPJ Precision Oncology] The authors analyzed the differentiation trajectory of epithelial cells in different disease stages from gastric antrum biopsies in patients with precancerous lesions and early gastric cancer using single-cell sequencing data.

[Journal of Translational Medicine] Researchers found that cathepsin E drives colorectal cancer progression by stabilizing ZNF326 via ADP-ribosylation and activating TGF-β/SMAD pathway, while facilitating tumor immune evasion.